Sana Biotechnology (SANA) Accumulated Expenses (2020 - 2026)

Sana Biotechnology has reported Accumulated Expenses for 7 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Accumulated Expenses fell 14.43% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 14.43% YoY) and the FY2025 annual result came in at $8.8 million, down 33.28% from the prior year.
• Accumulated Expenses declined to $2.8 million in Q1 2026 per SANA's latest filing, from $8.8 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $21.3 million in Q2 2024 and troughed at $2.0 million in Q3 2025.
• A 5-year average of $7.3 million and a median of $5.2 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 76.08% in 2023, then jumped 236.38% in 2024.
• Over 5 years, Accumulated Expenses stood at $16.5 million in 2022, then slumped by 76.08% to $3.9 million in 2023, then surged by 236.38% to $13.2 million in 2024, then slumped by 33.28% to $8.8 million in 2025, then tumbled by 68.37% to $2.8 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.8 million, $8.8 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.